Certolizumab pegol reduces symptoms in patients with moderately to severely active Crohn's disease - Commentary

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	32-33
Number of pages	2
Journal	Evidence-Based Gastroenterology
Volume	9
Issue number	2
DOIs	https://doi.org/10.1097/EBG.0b013e3181726026
State	Published - May 2008

ASJC Scopus subject areas

@article{ec4815a2d1ff48cab801f0f7554d4eda,

title = "Certolizumab pegol reduces symptoms in patients with moderately to severely active Crohn's disease - Commentary",

author = "Loftus, {Edward V.}",

year = "2008",

month = may,

doi = "10.1097/EBG.0b013e3181726026",

language = "English (US)",

volume = "9",

pages = "32--33",

journal = "Evidence-Based Gastroenterology",

issn = "1527-8557",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Certolizumab pegol reduces symptoms in patients with moderately to severely active Crohn's disease - Commentary

AU - Loftus, Edward V.

PY - 2008/5

Y1 - 2008/5

UR - http://www.scopus.com/inward/record.url?scp=43249098520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43249098520&partnerID=8YFLogxK

U2 - 10.1097/EBG.0b013e3181726026

DO - 10.1097/EBG.0b013e3181726026

M3 - Comment/debate

AN - SCOPUS:43249098520

SN - 1527-8557

VL - 9

SP - 32

EP - 33

JO - Evidence-Based Gastroenterology

JF - Evidence-Based Gastroenterology

IS - 2

ER -